These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37443712)

  • 1. Statins in Chronic Kidney Disease-Effects on Atherosclerosis and Cellular Senescence.
    Fularski P; Krzemińska J; Lewandowska N; Młynarska E; Saar M; Wronka M; Rysz J; Franczyk B
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephroprotective and clinical potential of statins in dialyzed patients.
    Rysz J; Aronow WS; Stolarek RS; Hannam S; Mikhailidis DP; Banach M
    Expert Opin Ther Targets; 2009 May; 13(5):541-50. PubMed ID: 19368496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and the development of atherosclerosis.
    Mizuno Y; Jacob RF; Mason RP
    J Atheroscler Thromb; 2011; 18(5):351-8. PubMed ID: 21427505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease.
    Liu XQ; Jiang TT; Wang MY; Liu WT; Huang Y; Huang YL; Jin FY; Zhao Q; Wang GH; Ruan XZ; Liu BC; Ma KL
    Front Immunol; 2021; 12():796383. PubMed ID: 35082785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.
    Wojtaszek E; Oldakowska-Jedynak U; Kwiatkowska M; Glogowski T; Malyszko J
    Oxid Med Cell Longev; 2021; 2021():6651367. PubMed ID: 33628373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches.
    Düsing P; Zietzer A; Goody PR; Hosen MR; Kurts C; Nickenig G; Jansen F
    J Mol Med (Berl); 2021 Mar; 99(3):335-348. PubMed ID: 33481059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10).
    Miyata R; Hiraiwa K; Cheng JC; Bai N; Vincent R; Francis GA; Sin DD; Van Eeden SF
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):1-11. PubMed ID: 23756175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential vascular benefits of statins.
    Kinlay S
    Am J Med; 2005 Dec; 118 Suppl 12A():62-7. PubMed ID: 16356810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
    Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
    Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation.
    Obialo CI; Ofili EO; Norris KC
    Int J Environ Res Public Health; 2018 Dec; 15(12):. PubMed ID: 30518032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity.
    Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S
    Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.
    Nitta K
    Clin Exp Nephrol; 2012 Aug; 16(4):522-9. PubMed ID: 22722878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].
    Zavidić T; Lodeta B; Lovrinić Đ
    Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL-cholesterol lowering and renal outcomes.
    Waters DD
    Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.